You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Contraceptive testing for semen availability in male monkeys
SBC: EPPIN PHARMA INC Topic: NICHDDESCRIPTION provided by applicant The global contraceptives market was valued at $ billion in and is expected to grow at a CAGR of from to to reach an estimated value of $ billion in An important high impact driver of this market is the prevalence of unintended pregnancies In the US there are million unintended pregnancies annually through inconsistent or ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Developing therapeutic inhibitors of CIB1 for breast cancer
SBC: Reveris Therapeutics Topic: 102DESCRIPTIONprovided by applicantBreast cancer is the most common malignancy in women living in the USwith more thannew cases diagnosed each yearand an estimatedwomen dying from the disease inGreater thanof these diagnoses are classified as triple negative breast cancerTNBCwhich is considered among the most aggressive breast cancer sub typeswith the worst prognosisTNBC is difficult to treat because ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
New Class of Bright, Sharp, Tunable Red/Far-Red Fluorophores for Flow Cytometry
SBC: Nirvana Sciences, Inc. Topic: NIBIBDESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques used in immunology basic research and clinical medicine In basic research FC is a primary tool for understanding disease development at the cellular and subcellular levels In the rapidly developing field of immunotherapy FC is an indispensable tool for monitoring the effec ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter (BioSphincter) to Treat Fecal Incontinence
SBC: CELLF-BIO LLC Topic: 300DESCRIPTION provided by applicant We propose to bring to market a novel regenerative medicine based therapy for fecal incontinence FI FI is the recurrent uncontrolled passage of fecal material The Internal Anal Sphincter IAS is responsible for maintaining anorectal continence Function of the IAS is dependent upon the neuromuscular integrity of both the smooth muscle and the intrinsic en ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Delivery of peptides for inducing voiding associated with neurological retention
SBC: Dignify Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Neurological conditions such as multiple sclerosis Parkinsonandapos s disease dementia spina bifida diabetes stroke and spinal cord injury SCI can result in loss of voluntary control over bladder and bowel function often producing both incontinence and retention of urine and stools in the same patient This has a profound impact on the mental and phy ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides
SBC: Initos Pharmaceuticals LLC Topic: 999DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecule ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model
SBC: Cytex Therapeutics, Inc. Topic: NIAMSDESCRIPTION provided by applicant The treatment of large cartilage lesions is a difficult clinical problem for which there are few good solutions Left untreated these lesions tend to degenerate to chronic pain and osteoarthritis OA ultimately requiring a total joint replacement For patients suffering from knee OA and in particular unicompartmental OA unicondylar knee arthroplasty UK ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: NIAMSDESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto
SBC: Nirvana Sciences, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC. Topic: NIAAbstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health